HOMOCYSTEINEMIA STUDY

心血管死亡和发病率仍然是主要的长期 肾移植患者的并发症脂质和 脂蛋白可能部分导致风险增加;然而， 可能涉及其他风险因素。同型半胱氨酸正在迅速成为一种 冠状动脉、颈动脉和 外周动脉粥样硬化事件。有早期证据表明， 同型半胱氨酸水平通常发生在肾移植患者或 慢性肾脏疾病，但适当的诊断或治疗 方法尚未确立。 拟议的研究包括： 1.）高同型半胱氨酸血症的发生率和严重程度以及 将评估适当的诊断方法。 2.）的情况。将评价高同型半胱氨酸血症的原因。他们将 包括肾功能、营养、遗传和 合并用药。 3.）第三章使空腹和蛋氨酸后恢复正常的治疗方法 将评价负荷高半胱氨酸水平。 4.）总体目标将是开发简单的临床算法， 同型半胱氨酸疾病的诊断和治疗。

Cardiovascular death and morbidity continue to be major long-term complications in renal transplant patients. Abnormalities in lipids and lipoproteins may partially contribute to the increased risk; however, other risk factors may be involved. Homocysteine is rapidly emerging as an important risk factor for the development of coronary, carotid and peripheral atherosclerotic events. There is early evidence that elevated homocysteine levels commonly occur in patients with renal transplants or chronic renal disease, but the appropriate diagnostic or therapeutic approaches have not been established. The proposed studies include: 1.) The frequency and severity of hyper-homocysteinemia and the appropriate diagnostic approach will be evaluated. 2.)The causes of hyper-homocysteinemia will be evaluated. They will include the influence of renal function, nutritional, genetic and concomitant medication. 3.) Therapeutic approaches to normalize both fasting and post-methionine load homocysteine levels will be evaluated. 4.) The overall goal will be to develop simple clinical algorithms for the diagnosis and treatment of homocysteine disorders.